BRCA1 and BRCA2 / Posted 1 year ago
PARTNER: Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or Gbrca
Surgery is often used for early breast cancers.
Sometimes you have chemotherapy before surgery. This is called neo adjuvant chemotherapy. It can shrink the cancer and make the surgery more successful.
In this trial, researchers are looking at whether adding a drug called olaparib (also called Lynparza) improves neo adjuvant chemotherapy.
Olaparib is a type of biological therapy called a PARP-1 inhibitor. PARP is a protein that helps cells to repair. Doctors think that olaparib can stop the cancer cells from repairing themselves.
In this trial, people have 1 of the following:
- chemotherapy with olaparib
The chemotherapy drugs used in this trial are:
These are commonly used to treat breast cancer but are not routinely used to treat early breast cancer. Doctors want to use them in this trial because research has shown that the combination of these drugs is a successful treatment.
The main aims of the trial are to:
- find out how well olaparib and chemotherapy works as a treatment
- learn about the side effects